Immutep Ltd ( (PRRUF) ) has released its Q2 earnings. Here is a breakdown of the information Immutep Ltd presented to its investors.
Immutep Ltd is a clinical-stage biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. The company is listed on the Australian Securities Exchange and NASDAQ. In its latest earnings report for the half-year ended December 31, 2024, Immutep reported a significant increase in other income, up 77% to A$7.28 million, driven by higher interest and grant income. However, the company also experienced a 5% increase in its net loss, totaling A$22.38 million, primarily due to elevated research and development expenses. Key highlights include the initiation of the TACTI-004 Phase III trial for non-small cell lung cancer and promising results from other clinical trials such as TACTI-003 and AIPAC-003. Immutep’s financial position remains strong, with cash reserves of A$159.26 million, providing a cash runway until the end of 2026. Looking ahead, Immutep is poised to advance its clinical programs, with management optimistic about bringing its lead product candidate, eftilagimod alpha, to market.